Our team will be unavailable from December 25, 2023, to January 1, 2024.
We will resume operations on January 2, 2024. Wishing you a joyful holiday season!

MUSC SETS NEW RECORD AS STATE’S BIOMEDICAL RESEARCH LEADER WITH MORE THAN $328 MILLION IN FUNDING

The Medical University of South Carolina has broken its own record as the state’s leader in garnering extramural funding for biomedical research. MUSC set a new high-water mark in FY2021, bringing in more than $328 million. The previous MUSC record for annual biomedical research funding was more than $284 million, set in FY2019.  

“Being the state’s leader in biomedical research funding year after year is a significant accomplishment, and we applaud the passion and expertise of our dedicated scientists and their teams,” said David J. Cole, M.D., FACS, MUSC president. “Even so, reaching another record-breaking number is not an end in itself. The true impact of MUSC research is reflected in how we translate discoveries into new modalities of care and life-changing therapeutics. Research is a dynamic force that fuels how we fulfill our mission to lead health innovation for the lives we touch,” he added. 

Lori McMahon Ph.D., vice president for Research, called the accomplishment outstanding, especially during a period when being awarded research grant funding has become more intensely competitive than ever before. No other publicly assisted academic institution in South Carolina consistently garners near $250 million in research funding year after year. 

MUSC research focuses on a wide variety of areas including cancer, community health, drug discovery, health disparities, inflammation and fibrosis, neuroscience, oral health, stroke and addiction.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.